Inclusion Criteria:

- At least 18 years of age

- Histological or cytological diagnosis of AOC

- Stable disease (SD) or progression at time of study entry Recurrent or progressive
AOC ≥ 90 days of duration of response for first-line therapy

- Measurable disease defined by RECIST criteria

- ECOG Performance Status of 0, 1, or 2

- Life expectancy > 3 months

- Adequate bone marrow, Renal, Hepatic reserve:

- absolute neutrophil (segmented and bands) count (ANC) ≥ 1500 cells/μL

- platelet count ≥ 100,000 cells/μL

- hemoglobin ≥ 9 g/dL

- Total bilirubin ≤ 1.5 X ULN

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.0 X ULN

- Alkaline Phosphatase (ALP) ≤ 2.0 X ULN

- Serum creatinine < 1.5mg/dL or calculated creatinine clearance > 60mL/min

- Signed a written informed consent

Exclusion Criteria:

- Active infection

- Symptomatic brain lesion

- Any other type of cancer during the previous 5 years except appropriately treated
basal cell carcinoma of the skin or in situ carcinoma of the cervix Severe concurrent
diseases

- Prior anticancer therapy within 4 weeks before enroll

- Active pregnancy test and Pregnant or nursing women

- Participation in any investigational drug study within 28 days prior to study entry